LFCR - Lifecore Biomedical Inc.

LFCR - Lifecore Biomedical Inc.

https://www.lifecore.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Lifecore Biomedical ( LFCR ) Soars 10.8%: Is Further Upside Left in the Stock?

Zacks Commentary • 3 days, 6 hours ago • score: 0.38

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Lifecore Biomedical to Participate in Upcoming Investor Conferences

GlobeNewswire • 1 week, 5 days ago • score: 0.12

CHASKA, Minn., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Lifecore Biomedical, Inc. ( NASDAQ: LFCR ) ( "Lifecore" ) , a fully integrated contract development and manufacturing organization ( "CDMO" ) , today announced that the company will participate in multiple upcoming investor conferences.

Lifecore Biomedical ( LFCR ) Reports Q4 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.10

Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of -11.11% and +1.96%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 month, 4 weeks ago • score: 0.29

CHASKA, Minn., July 17, 2025 ( GLOBE NEWSWIRE ) -- Lifecore Biomedical, Inc. ( NASDAQ: LFCR ) ( "Lifecore" ) a fully integrated contract development and manufacturing organization ( "CDMO" ) , today announced that on July 11, 2025, the Lifecore compensation committee approved grants under ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.

52W High

$8.85

52W Low

$4.33

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.64

Valuation

Attractive

As of 2025-05-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

8.67

EV/EBITDA (<8 favorable)

8.11

EV/Revenue (<3 favorable)

3.14

P/S (TTM) (<3 favorable)

2.19

P/B (<3 favorable)

210.84

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.99%

Institutions (25–75% balanced)

76.48%

Shares Outstanding

37,407,900

Float

19,024,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-05-31 (Overview)

Revenue (TTM)

128,867,000

Gross Profit (TTM)

40,298,000

EPS (TTM)

-1.27

Profit Margin (>10% good)

-0.30%

Operating Margin (TTM) (higher better)

0.08%

ROE (TTM) (>15% strong)

-0.76%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.04

Momentum

Bearish momentum

Value

-0.0028

Previous

-0.0089

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025